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Abstract
Introduction: Today, ligands that bind to fibrillar b-amyloid are detectable by Positron Emission Tomography (PET) allowing for
in vivo visualization for Abeta burden. However, amyloid plaques detection per se does not establish Alzheimer’s Disease
diagnosis. In this sense, the utility of amyloid imaging to improve clinical diagnosis was settled only for specific clinical scenarios and
few studies have assessed amyloid molecular neuroimaging in a broader clinical setting. The aim of this study is to determine the
frequency of PiB amyloid findings in different diagnostic syndromes grouped into high and low probability pre- test categories,
taking into account pre-test clinical assumption of the presence of AD related pathology. Methods: 144 patients were assigned
into categories of high or low pretest probability according to clinical suspicion of AD pathology. The high probability group
included: amnestic Mild Cognitive Impairment (MCI), amnestic and other domains MCI, Dementia of Alzheimer’s Type (DAT),
Posterior Cortical Atrophy (PCA), logopenic Primary Progressive Aphasia (PPA), Cerebral Amyloid Angiopathy and mixed
dementia. The low assumption group included: normal controls, non-amnestic MCI, non-logopenic PPA and Frontotemporal
Dementia (FTD). Results: Only normal controls and DAT patients (typical and atypical presentation) were the most consistent
across clinical and molecular diagnostics. MCI, non-logopenic PPA and FTD were the syndromic diagnoses that most dis-
crepancies were found. Discussion: This study demonstrates that detecting in vivo amyloid plaques by molecular imaging is
considerably frequent in most of the dementia syndromes and shows that there are frequent discordance between molecular
diagnosis and clinical assumption.
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Introduction
Amyloid plaques are a hallmark in the pathophysiology of
Alzheimer’s disease (AD) and constitute one of the earliest
events in this disease.1 Today, ligands that bind to fibrillar
b-amyloid (Abeta) are detectable by positron emission tomo-
graphy (PET) allowing for in vivo visualization for Abeta bur-
den.2 Carbon11-labeled Pittsburgh compound B (11C-PIB), a
tioflavin-radiolabeled analog, was the first ligand to be developed
and is the most extensively studied. There is high correlation
between PIB-positive in vivo amyloid findings and autopsied
amyloid cases.2 Moreover, good interreader agreement levels has
shown to be reproducible.3 However, since several longitudinal
studies of aging have shown that brain amyloid can be found in
cognitively normal elderly people and also combined with other
existing pathologies, amyloid plaques are only part of a more
complex pathological mechanism and detection per se does not
establish AD diagnosis.1 Therefore, the utility of amyloid ima-
ging to improve clinical diagnosis was settled only for specific
clinical scenarios.4,5 Published data on amyloid imaging usually
selects patients with typical presentation, which are easier to cate-
gorize compared to the patients with routine encounter in daily
practice at our memory clinic. Few studies have assessed amyloid
molecular neuroimaging in a broader clinical setting.6
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The aim of this study is to determine the frequency of PIB
amyloid findings in different diagnostic syndromes grouped into
high and low probability pretest categories, taking into account
pretest clinical assumption of the presence of AD-related pathol-
ogy. Then we compare concordance with molecular diagnosis in
each syndromic diagnosis. Finally, we reviewed some potential
clinical consequences regarding PET amyloid scans in clinical
setting.
Material and Method
Study Population and Baseline Evaluations
This is an observational retrospective study designed to
describe our initial experience with the use of amyloid PET
imaging in routine daily patients seen in an Aging and Memory
Center, Neurological Research Institute (FLENI), Buenos
Aires, Argentina. We included for analysis the first 178 patients
who underwent 11C-PIB-PET in our center from December
2012 to December 2013. Since we are a referral center for cog-
nitive disorders, patients of our clinic tend to have atypical
rather typical presentation. In all, 40 of these patients belong
to the study protocol Argentina-Alzheimer’s Disease Neuroi-
maging Initiative (ADNI Arg); 13 patients were referred for the
PET test from the Kremer’s Neuropsychiatric Institute in Cór-
doba, Argentina; the rest of the patients were either referred for
PET test from our Aging and Memory Center or were inpati-
ents from the Neurology Department from FLENI. Thirty-
four patients who were not evaluated by our team or who
lacked the baseline neuropychological or neuropsychiatric
assessment were excluded from this analysis. Finally, 144
patients were included for analysis.
All patients had a standard baseline evaluation performed by
a doctor experienced in memory disorders (neurologists, psy-
chiatrists, or geriatricians) that included a medical interview,
informant-based clinical history taking, physical, and neurolo-
gic examination. Performed blood tests to rule out reversible
causes of dementia included basic chemistry, cell blood count,
calcium, thyroid test, HIV serology, levels of vitamin B12,
folic acid, and homocysteine levels. Furthermore, neuropsy-
chological assessment was performed by a neuropsychologist
and included:
 Mini-Mental State Examination (MMSE),7
 Wechsler logical memory (WMT),8
 Rey auditory verbal learning test (RAVLT),9
 Boston naming test,10
 Semantic and phonological fluency for language
evaluation,11
 Direct and reverse digit span,12
 Trail making test (TMT),13 and
 Frontal assessment battery (FAB) for executive
function.14
All patients also underwent magnetic resonance imaging
(MRI) of the brain including T1, T2, fluid-attenuated inversion
recovery, and gradient-recalled echo, and diffusion-weighted
imaging sequences and images were saved in Kodak Care-
stream System from FLENI for clinical reviewing.
Patient’s Classification Based on Clinical Data
Based on pre-PET results obtained, patients were classified by
dementia experts into the following groups:
1. Normal controls
2. Amnestic-type mild cognitive impairment (a-MCI):
patients with memory complaint with only abnormal
Z score below 1.5 standard deviation (SD) from the
mean (matched by age and sex) in the memory tests
(WMT8 and RAVLT9) without functional impairment.
3. Amnestic multidomain mild cognitive impairment
(am-MCI): patients with memory complaint and
alteration in other domains with a Z score below 1.5
SD, without functional impairment.
4. Nonamnestic mild cognitive impairment (nonamnestic-
MCI): patients with any cognitive complaint without
evidence of memory impairment but with significant
impairment in other cognitive domains with a Z score
below 1.5 SD. They had no functional impairment.
5. Dementia of Alzheimer’s type (DAT): based on prob-
able Alzheimer’s Dementia National Institute of Neu-
rological and Communicative Disorders and Stroke
Alzheimer’s Disease and Related Disorders Associa-
tion (NINCDS-ADRDA) clinical criteria.15
6. Behavioral variant of frontotemporal dementia based
on the Rascovsky et al criteria16
7. Primary progressive aphasia (PPA): patients with lan-
guage alterations based on Mesulam PPA criteria17 and
its variants according Gorno-Tempini et al criteria18
8. Cortical posterior atrophy: patients with visual spatial
and parietal alterations based on a revision from
Crutch et al criteria.19
9. Mixed dementia: based on probable DAT defined by
NINCDS-ADRDA criteria and evidence of cerebro-
vascular pathology in brain MRI.
10. Other degenerative disorders including 2 patients with
clinical and neuroimaging finding of probable cerebral
amyloid angiopathy (CAA) according to the Boston
criteria20; and 1 patient fulfilled clinical features for
corticobasal syndrome (CBS).
Based on their respective physiopathologies and using their
possible relation to amyloid deposits as the main variable, all
9 aforementioned disease categories were assigned into groups
of either high or low pretest amyloid deposit probability. Within
the high probability group, we included patients in the a-MCI,
am-MCI, DTA, PCA, CAA, logopenic variant of PPA, and
mixed dementia group. The low probability group comprised the
control group and patients with clinical diagnosis of nonamnes-
tic MCI, bvFTD, nonlogopenic-PPA (semantic variant and non-
fluent agrammatic aphasia), and CBS.
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Synthesis and Purification of 11C-PIB-PET
The synthesis of 11C-PIB is performed in the Tracer LAB FXC-
PRO (General Electric RIS (Radiology Information System)
Carestream); the process’ duration from the reception of 11C-
CO2 takes approximately 25 minutes and another 10 minutes
for the purification. The purification is performed through the
differential interaction among the components of the row prod-
uct, the stationary phase, and the mobile phase. The final pur-
ification is performed within the synthesis module. The final
result is a mixed solution of the mobile phase with a volume
of 28 mL of physiologic solution with a content of less than
10% of ethanol and 200 mCi approximately of 11C-PIB. The
final result of the reaction is of 10%.
At 50 minutes of the endovenous infusion of 10 mCi of
11C-PIB (Pittsburgh Component) volumetric multislice compu-
terized tomography (CT) brain images were obtained using
PET/CT Discovery 690 GE equipment (General Electric RIS
(Radiology Information System) Carestream). Images were
obtained using a nonuniform attenuation correction with CT.
Axial, coronal, and sagittal images were obtained either with MRI
and/or CT.
Visual Analysis of PET
Images were viewed and analyzed by 2 nuclear medicine phy-
sicians, blinded to the clinical data of the patients. Both read-
ers are experienced in 11C-PIB interpretation as they are
currently part of the PET team of the ongoing ADNI Arg since
2011.21 The presence or absence of cortical brain amyloid and
its spatial distribution was analyzed in a qualitative way using
visual color linear scales. Based on the concentration of activ-
ity of 11C-PIB, the degree of cortical retention was classified
as positive or negative. The interobserver variability was 5%.
No other semiquantitative or quantitative assay was per-
formed from the PET images.
Statistic Analysis
The SPSS Statistical package (version 19.0) was used for the
data analyses. Demographic variables (age and education) and
neuropsychological battery scores were compared by the Stu-
dent’s t test. Pearson’s chi-square test was employed for catego-
rical data (gender). Assumption of variance homogeneity was
assessed using Levene’s test. In order to investigate the effects
of age and education, we conducted an analysis of covariance
(ANCOVA) adjusted for age and education in years followed
by Bonferroni’s post hoc analysis. Neuropsychological test bat-
tery scores were assessed by the raw scores of all included tests.
We applied the Spearman’s correlation 2-tailed analysis test to
investigate the relation between the demographic variables and
neuropsychological–biological data. Effect size was calculated
using j coefficient for the Pearson’s chi-square test. A P level
of <.05 was considered as statistically significant level.
The 2 2 contingency analysis was used to assess the accu-
racy of the 11C-PIB-PET visual interpretation when used to dis-
tinguish high from low pretest probability and to determine the
test sensitivity and specificity. In order to assess the effect of
age on diagnostic accuracy, the cohort was split into 2 groups
according to the median age of the sample, with younger
(68 years) and older (>68 years). The above-mentioned anal-
yses were performed on both categories. Finally, we compared
differences in clinical and neuropsychological variables in the
PIBþ to PIB groups.
Results
Table 1 shows the sociodemographic characteristics and
MMSE scores of the participants, stratified by clinical diagno-
sis. Clinical diagnoses were divided into high or low pretest
probability categories based on the association of the clinical
syndrome with predicted histopathology. Sociodemographic
characteristics and neuropsychological test battery results for
Table 1. Demographic Data of Diagnostic Groups.a
n
Age at Scan Education MMSE
Gender, Female, % (n)Mean SD Mean SD Mean SD
Controls 17 63.35 6.86 15.94 2.57 29.63 0.89 64.7 (11)
a-MCI 32 69.97 7.69 14.07 4.63 27.31 2.80 53.1 (17)
am-MCI 20 70.35 7.73 14.77 3.90 27.24 3.05 65.0 (13)
Nonmemory-MCI 18 67.11 5.56 13.67 3.12 28.19 1.60 27.8 (5)
DAT 21 70.14 5.78 13.37 3.45 23.29 4.01 66.7 (14)
bvFTD 6 61.60 14.36 15.00 4.24 23.00 9.54 66.7 (4)
PPA 11 61.27 10.10 14.60 4.51 24.43 4.39 54.5 (6)
Logopenic PPA 4 67.25 5.25 13.50 2.12 24.50 2.12 75.0 (3)
PCA 5 65.00 11.25 13.00 4.55 23.00 7.52 40.0 (2)
Amyloid angiopathy 2 66.50 3.54 9.00 0.10 13.00 0.10 0 (0)
Mixed dementia 7 70.43 6.11 14.60 2.61 21.40 6.39 57.1 (4)
CBD 1 70.00 24.00 100 (1)
Abbreviations: MMSE, Mini-Mental State Examination; a-MCI, amnestic mild cognitive impairment; am-MCI, amnestic multidomain mild cognitive impairment;
DAT, dementia of the Alzheimer type; bvFTD, behavioral variant frontotemporal dementia; PPA, primary progressive aphasia; PCA, posterior cortical atrophy;
CBD, corticobasal degeneration.
aAll values are means and standard deviations (SDs), or percentages.
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both groups are listed in Table 2. Both groups were similar with
respect to gender (w2 ¼ 0.723, P ¼ .487), years of education
(t ¼ 1.14, P ¼ .26), and years of disease evolution (t ¼
1.60, P ¼ .11). Compared to the low pretest probability
group, the high pretest probability patients were older (t ¼
4.17, P < .001), had lower MMSE (t ¼ 4.35, P ¼ .01),
RAVLT total (t ¼ 4.35, P < .001), RAVLT delayed (t ¼
5.98, P < .001) and RAVLT recognition (t ¼ 3.54, P < .001),
backward digit span (t ¼ 2.52, P ¼ .01), TMT-A (t ¼ 2.52,
P ¼ .01), and TMT-B (t ¼ 2.58, P ¼ .01) scores. Covarying
for age or education had no effect on these results (ANCOVA
results not shown).
Positive 11C-PIB scans by visual inspection was positively
correlated with age (P ¼ .17) and negatively with years of edu-
cation (P < .001), MMSE, RAVLT total, delayed and recogni-
tion scores (P < .001), category fluency test (P¼ .002), TMT-A
(P < .001), and TMT-B (P ¼ .001).
We include 144 patients. In all, 63% (91 of 144) was
assigned to the high pretest probability subgroup (Table 3), and
37% (53 of 144) was assigned to the low pretest probability
subgroup (Table 4) based on the clinical probability of having
an underlying AD neuropathology.
Overall concordance between scan results and clinical diag-
nosis was 72.6% for high pretest probability and 73.6% for low
pretest probability. Of the high pretest probability patients,
68.8% (22 of 32) a-MCI, 60% (12 of 20) am-MCI, 76.2%
(16 of 21) DAT, all the patients who had Logopenic-PPA (4
of 4) and PCA (5 of 5), both cases of CAA (2 of 2), and
71.4% (5 of 7) patients with mixed dementia had positive
11C-PIB scans by visual inspection. By contrast, the low pretest
probability group was more heterogeneous. In all, 5% (1 of 17)
control patients, 33% (6 of 18) nonmemory-MCI, 33% (2 of 6)
bvFTD, and 45% (5 of 11) patients with PPA showed positive
11C-PIB scans. Figure 1 shows the percentage of concordance
between clinical diagnosis and 11C-PIB PET results.
Our analyses indicated that a positive 11C-PIB (72.5% vs
26.4%, w2 ¼ 28.843, P < .001) was more likely within the high
probability group than the low probability group. These results
did not change when young and older groups were analyzed
separately. Our analyses also indicated that in our sample there
is a significant association between pretest probability and
11C-PIB result (j ¼ .448, df ¼ 1, P < .0001).
The test sensitivity, specificity, and accuracy of visual inter-
pretation of 11C-PIB are summarized in Table 5. The visual
interpretation of 11C-PIB showed sensitivity (0.72), specificity
(0.73), and accuracy (0.72) to differentiate between high from
low pretest probability. Age appeared to have an impact on sen-
sitivity but not on specificity or accuracy in 11C-PIB. A reduc-
tion in sensitivity was observed in the younger group when
compared with the older patients.
Table 3. Results of 11C-PIB Scans by Visual Inspection in Patients





a-MCI 32 22 68.8
am-MCI 20 12 60.0
DAT 21 16 76.2
Logopenic PPA 4 4 100.0
PCA 5 5 100.0
Amyloid angiopathy 2 2 100.0
Mixed dementia 7 5 71.4
Abbreviations: a-MCI, amnestic mild cognitive impairment; am-MCI, amnestic
multidomain mild cognitive impairment; DAT, dementia of Alzheimer’s type;
PPA, primary progressive aphasia; PCA, posterior cortical atrophy; PIB,
Pittsburgh compound B; AD, Alzheimer’s disease.
Table 4. Results of 11C-PIB Scans by Visual Inspection in Patients with




Controls 17 1 5.0
Nonmemory-MCI 18 6 33.0
bvFTD 6 2 33.0
PPA 11 5 45.0
CBD 1 0 0
Abbreviations: bvFTD, behavioral variant frontotemporal dementia; PPA,
primary progressive aphasia; CBD, corticobasal degeneration; PIB, Pittsburgh
compound B; AD, Alzheimer’s disease; MCI, mild cognitive impairment.






Mean SD Mean SD t P
Age 65.89 8.35 69.66 7.18 4.17 <.001
Gender (male/female) 26/27 38/53 0.723 .487
Years of evolution 2.02 1.79 2.63 2.12 1.60 .11
Education 14.73 3.19 13.90 3.97 1.14 .26
MMSE 27.65 3.67 25.46 4.51 2.71 .01
RAVLT total 35.56 10.60 26.77 8.64 4.35 <.001
RAVLT delayed 5.64 3.59 1.86 2.56 5.98 <.001
RAVLT recognition 11.09 3.15 8.11 4.25 3.54 <.001
Category fluency test 16.86 5.50 15.21 5.38 1.47 .14
Phonological fluency
test
13.20 5.78 12.57 5.88 0.51 .60
Forward digit span 5.90 1.16 5.70 1.30 0.74 .46
Backward digit span 3.87 0.88 3.29 1.13 2.52 .01
TMT-A 47.29 25.69 76.19 65.18 2.52 .01
TMT-B 111.25 71.83 157.78 85.72 2.58 .01
GDS 3.21 3.01 2.48 2.18 1.19 .24
NPI-Q 7.39 7.24 5.04 4.74 1.55 .12
FAQ 5.67 4.90 6.76 6.99 0.60 .55
Abbreviations: MMSE, Mini-Mental State Examination; RAVLT, rey auditory
verbal learning test; TMT-A, trail making test part A; TMT-B, trail making test
part B; GDS, geriatric depression scale; NPI-Q, neuropsychiatric inventory
questionnaire; FAQ, functional activities questionnaire.
aAll values are means and standard deviations (SDs), or percentages. Pearson’s
chi-square test. Student’s t test, 2-tailed, and unequal variance.
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Discussion
In the present study, we described findings of brain amyloid
deposition using 11C-PIB-PET in a large sample of routine
patients diagnosed with cognitive prevalent syndromes con-
sulting at a memory clinic in Buenos Aires. In general, ele-
vated frequency of positive PIBs was detected in the high
probability pretest group and elevated frequency of negative
PET studies was observed in the low pretest probability
group. However, considerable differences were evident
between clinical diagnosis and results of molecular imaging
in both groups. The sample was negative in 29.67% of the
patients in the high probability group, whereas it was positive
in 26.42% of patients in the low probability, in which amyloid
deposition was not expected. When calculating sensitivity and
specificity according to high and low pretest probability, PIB
sensitivity was lower in younger when compared to older
ones, whereas specificity remains the same (Table 4). Other
studies have shown discrepancy between clinical and molecu-
lar diagnosis of almost 39%.5 These results that significantly
contradict the initial clinical assumption may entail conse-
quences in relation to patient management. Given that these
consequences may be different in patients from both low and
high pretest probability groups, it is important to analyze con-
cordances and implications for each syndromic category.
Patients diagnosed with a-MCI or am-MCI had the lowest
rates of concordance when compared to molecular diagnosis
in the high pretest probability group (68.8% and 60%, respec-
tively). According to the new diagnostic recommendations, an
intermediate risk of MCI due to AD exists in patients in whom
brain amyloid was detected. Higher risk is conferred to patients
with neurodegenerative markers such as t in CSF, MRI hippo-
campal atrophy, and fludeoxyglucose-PET AD signature, when
added to amyloid detection.22 However, PIB did predict pro-
gression to AD in longitudinal studies in patients with MCI
without neurodegeneration markers.23 Some studies consider
a-MCI and positive PIB scenario as prodromal stage of
AD.24 Finally a-MCI and am-MCI have increased AD conver-
sion risk when combined with positive PIB. Preventive strate-
gies on risk factor control should be emphasized for this group
when considering the additional value of molecular imaging.25
More interesting are patients with a-MCI having negative PIB
(31.2%). According to current diagnostic criteria recommenda-
tions, this group has a lower risk of AD conversion.22 Consider-
ing amyloid deposition occurs between 10 and 20 years before
clinical manifestations,1 these patients have a very low probabil-
ity of developing AD. Patients with MCI having negative PIB
correspond to a scenario that reinforces the need to search for
other pathologies. Further tests and treatments on them are unne-
cessary and should be avoided. In this regard, the US Food and
Drug administration has recently accepted the negative pre-
dictive value of fluorine-based amyloid tracer florbetapir26,27
(which has a longer half-life and allowed its commercialization).
In this context, PIB was studied more than florbetapir, with the
same negative predictive value applying to nonamnestic patients
with MCI having negative PIB. On the other hand, positive PIB
in patients with nonamnestic MCI does not improve diagnostic
certainty. Although the risk of conversion to AD is increased,28
other non-AD pathologies cannot be ruled out.
In the DAT group, 76% of these patients had positive PIB.
In this category, there is a high correlation between clinical and
molecular diagnosis. Perhaps clinical uncertainty at this stage
of disease is low, making molecular diagnosis redundant.2 Five
(23.8%) patients clinically diagnosed as having AD had nega-
tive PIB scans. In these patients, the possibility of a falsè-neg-
ative result could not be ruled out.29 However, non-AD
pathology in patients with AD-like phenotype is not uncom-
mon.30 Furthermore, AD-like phenotype was found in patients
with mutations in genes implicated in FTD (c9orf72).31 In our
sample, age of patients with AD was lower and MMSE average
performance was higher compared to other studies. Most
patients with AD were at a mild stage of the disease and part
of ADNI-Arg. In the rest of the cases with DAT, PIB was per-
formed in early-onset cases. As our DAT sample corresponded
to mild and early-onset cases, not many differences were found
compared with the percentage of molecular agreement found in
aMCI (68.8%). Fewer requests for molecular imaging were
ordered in patients with more advanced disease, since molecu-
lar diagnosis does not change patient perspective. We con-
cluded there is strong pretest presumption of amyloid
deposition in the AD group and positive PIB may reinforce ini-
tial diagnosis in patients with AD. However, we consider PIB
clinically useful mainly in early-onset patients so as to rule out
Table 5. Sensitivity, Specificity, and Accuracy of 11C-PIB (Visual
Analysis).
Sensitivity Specificity Accuracy
High vs low pretest probability 0.72 0.73 0.72
Young (68 y) 0.68 0.75 0.72
Old (>68 y) 0.75 0.73 0.75


























Figure 1. Percentage of concordance between clinical diagnosis and
carbon11-labeled Pittsburgh compound B (11C-PIB-PET) results. DAT
indicates dementia of the Alzheimer type; a-MCI, amnestic mild cog-
nitive impairment; am-MCI, amnestic multidomain mild cognitive
impairment; bvFTD, behavioral variant frontotemporal dementia;
PPA, Primary progressive aphasia; PCA, posterior cortical atrophy;
CBD, corticobasal degeneration.
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alternative diagnoses. Also, a negative amyloid scan may have
consequences in medication management, although no study to
date has assessed the value of antidementials in amyloid nega-
tive patients. Same considerations regarding patients with
mixed dementia apply, as they were defined as patients with
DAT with evidence of cerebrovascular disease and were
included in the high pretest probability group. In fact, these
patients have shown similar concordance rate to patients with
DAT (71.4%).
Regarding the other patients included in the high pretest
probability group (PCA, logopenic-PPA, and CAA), few con-
clusions can be drawn due to the small sample recruited. In
these patients, however, mean age was substantially low since
all cases were presenile onset. All patients had positive amy-
loid findings (maximum concordance). However, other differ-
ential diagnoses of young onset dementia should also be
considered (FTD, Lewy’s body disease, and Creutzfeldt-
Jakob’s disease).32 Establishing diagnosis of one of the latter
may have significant prognostic, therapeutic, and genetic
implications. Thus, presence or absence of amyloid in young
patients with atypical variants may be especially useful for
diagnosis and have particular impact on medical decision
making.
In patients included in the frontotemporal lobar degenera-
tion spectrum (which is considered a low probability pretest
group), results were heterogeneous with the lowest concor-
dance rates between categories. Two (33%) patients with beha-
vioral variant FTD (bvFTD) had a positive amyloid scan.33
These cases raise 2 possibilities: frontal variant AD34 or coex-
isting pathology (amyloid deposits in a patient with pathologi-
cal FTD). The remaining patients with bvFTD had negative
PIB scans. As mentioned previously, presence of AD biomar-
kers represented an exclusion criterion for Rascovsky et al.33
In patients with nonfluent/agrammatic or semantic variants of
PPA, presence of amyloid was unexpected (80%). Although
pathology finding overlap is usually found in PPA, the overlap
percentage is different for each variant: In nonfluent/agram-
matic PPA, AD pathology is found in 30% of autopsied
patients, and in the semantic variant, in less than 10%.35
Furthermore, clinical distinction between PPA variants may
be difficult in some patients, especially between nonfluent/
agrammatic and logopenic variants.36,37 In this sense, and in
addition to linguistic considerations, PIB might be useful to
identify true underlying pathology.
Finally, normal controls were incorporated into the low
probability pretest group. Almost all of them were part of
ADNI Arg. Only 1 of the 17 participants presented had a pos-
itive amyloid scan. Other articles reported that when PIB scans
are conducted in normal volunteers, 10% to 30% had positive
amyloid scans.38 The frequencies shown in these studies were
related to age and apolipoprotein E (APOE) genotype.39 The
mean age of our normal control group was the lowest of the
sample (APOE genotyping is still in process). Significance of
amyloid in normal volunteers remains uncertain and with no
appropriate indication to order PIB in normal cognitive partici-
pants up to date. So far, the limited longitudinal studies on the
patient show little agreement.39,40 Although these patients may
correspond to an AD preclinical stage (stage 1),41 studies have
shown that progression to AD is more related to neurodegen-
erative markers.42 Only 1 patient presented with parkinsonism
(CBS). The small number of patients recruited could respond to
the fact that several studies have shown frequent co-occurrence
of amyloid plaques in most of the extrapyramidal syn-
dromes.12,43 The lack of specificity reported in these particular
types of patients probably makes specialists avoid amyloid
neuroimaging. Moreover, CBS has also been described in rela-
tion to AD pathology.44,45
The present study has some limitations. This is a descrip-
tive study that only assesses amyloid detection frequencies
in different clinical syndromes. Sample selection was per-
formed in consecutive way; therefore, few patients were
recruited for some clinical syndromes and not every clinical
scenario was contemplated. As patients could not be matched
on sex, age, and educational level, this led to differences in
amyloid frequencies when compared to others studies. Espe-
cially, in the CN group which had the lowest mean age and,
as it was mentioned previously, amyloid findings in this group
are related to age and APOE status.38 In comparison with
other 18Fluor-labeled tracers studies, no quantitative image
analysis was made in this study (standardized uptake values
are used for normalizing injected dose and body weight).27,46
None of the patients has undergone brain autopsy for etiologi-
cal confirmation.
To conclude, it may be difficult to diagnose patients with
dementia syndromes based solely on clinical data due to over-
lap between distinct clinical syndrome and findings in neuro-
pathology. This study demonstrates that detecting in vivo
amyloid plaques by molecular imaging is considerably fre-
quent in most of the dementia syndromes. It further shows that
there are frequent discordance between molecular diagnosis
and clinical assumption. There is thus a significant need to
improve diagnostic accuracy. The PIB offers additional data
about the possible underlying mechanisms but not enough to
establish AD diagnosis. The additional value of PIB in the diag-
nostic process is different for each clinical syndrome. We
strongly believe amyloid detection may have significant impact
in the clinical setting of early AD onset (prodromal or clinical
stages) and for atypical features such as PCA and logopenic-
PPA variant. For the remaining categories described (bvFTD,
nonlogopenic PPA, and nonamnestic MCI), concordance rates
are lower and a positive amyloid scan does not establish cause
or coexistence of pathology.
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